Delcath Systems, Inc.

NasdaqCM:DCTH Stock Report

Market Cap: US$328.8m

Delcath Systems Valuation

Is DCTH undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of DCTH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

US$91.44
Fair Value
89.7% undervalued intrinsic discount
6
Number of Analysts

Below Fair Value: DCTH ($9.4) is trading below our estimate of fair value ($91.44)

Significantly Below Fair Value: DCTH is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for DCTH?

Key metric: As DCTH is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for DCTH. This is calculated by dividing DCTH's market cap by their current earnings.
What is DCTH's PE Ratio?
PE Ratio147.3x
EarningsUS$2.23m
Market CapUS$328.82m

Price to Earnings Ratio vs Peers

How does DCTH's PE Ratio compare to its peers?

The above table shows the PE ratio for DCTH vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average31.8x
TCMD Tactile Systems Technology
22.2x29.21%US$338.4m
TANA.F Tian'an Technology Group
68.2xn/aUS$39.4m
ELMD Electromed
26.7x19.46%US$200.5m
SMLR Semler Scientific
10.1x-126.57%US$393.5m
DCTH Delcath Systems
147.3x51.31%US$328.8m

Price-To-Earnings vs Peers: DCTH is expensive based on its Price-To-Earnings Ratio (147.3x) compared to the peer average (31.8x).

Price to Earnings Ratio vs Industry

How does DCTH's PE Ratio compare vs other companies in the US Medical Equipment Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
BDMD Baird Medical Investment Holdings
3xn/aUS$37.58m
PAVM PAVmed
0.1x-170.49%US$9.30m
MHUA Meihua International Medical Technologies
0.8xn/aUS$7.35m
No more companies available in this PE range
DCTH 147.3xIndustry Avg. 27.7xNo. of Companies9PE020406080100+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: DCTH is expensive based on its Price-To-Earnings Ratio (147.3x) compared to the US Medical Equipment industry average (27.7x).

Price to Earnings Ratio vs Fair Ratio

What is DCTH's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

DCTH PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio147.3x
Fair PE Ratio44x

Price-To-Earnings vs Fair Ratio: DCTH is expensive based on its Price-To-Earnings Ratio (147.3x) compared to the estimated Fair Price-To-Earnings Ratio (44x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst DCTH forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$9.40
US$23.50
+150.00%
14.06%US$30.00US$20.00n/a6
Oct ’26US$10.75
US$24.33
+126.36%
13.35%US$31.00US$21.00n/a6
Sep ’26US$11.02
US$24.33
+120.81%
13.35%US$31.00US$21.00n/a6
Aug ’26US$10.59
US$24.08
+127.37%
11.36%US$29.47US$21.00n/a6
Jul ’26US$12.76
US$24.08
+88.70%
11.36%US$29.47US$21.00n/a6
Jun ’26US$16.21
US$24.08
+48.54%
11.36%US$29.47US$21.00n/a6
May ’26US$12.08
US$22.50
+86.26%
6.67%US$25.00US$21.00n/a6
Apr ’26US$12.57
US$22.50
+79.00%
6.67%US$25.00US$21.00n/a6
Mar ’26US$14.17
US$21.83
+54.08%
7.20%US$25.00US$20.00n/a6
Feb ’26US$15.60
US$21.83
+39.96%
7.20%US$25.00US$20.00n/a6
Jan ’26US$12.04
US$21.33
+77.19%
10.00%US$25.00US$18.00n/a6
Dec ’25US$11.88
US$21.33
+79.57%
10.00%US$25.00US$18.00n/a6
Nov ’25US$10.50
US$21.33
+103.17%
10.00%US$25.00US$18.00n/a6
Oct ’25US$8.86
US$21.33
+140.78%
10.00%US$25.00US$18.00US$10.756
Sep ’25US$11.00
US$21.33
+93.94%
10.00%US$25.00US$18.00US$11.026
Aug ’25US$8.19
US$20.67
+152.34%
14.15%US$25.00US$16.00US$10.596
Jul ’25US$8.26
US$20.67
+150.20%
14.15%US$25.00US$16.00US$12.766
Jun ’25US$7.05
US$21.20
+200.71%
13.80%US$25.00US$16.00US$16.215
May ’25US$5.40
US$19.75
+265.74%
11.53%US$22.00US$16.00US$12.084
Apr ’25US$4.79
US$19.75
+312.32%
11.53%US$22.00US$16.00US$12.574
Mar ’25US$4.19
US$19.25
+359.43%
12.39%US$22.00US$16.00US$14.174
Feb ’25US$4.72
US$19.25
+307.84%
12.39%US$22.00US$16.00US$15.604
Jan ’25US$4.16
US$19.25
+362.74%
12.39%US$22.00US$16.00US$12.044
Dec ’24US$2.88
US$18.00
+525.00%
18.26%US$22.00US$13.00US$11.885
Nov ’24US$3.11
US$18.80
+504.50%
16.95%US$22.00US$13.00US$10.505
Oct ’24US$4.05
US$18.80
+364.20%
16.95%US$22.00US$13.00US$8.865
US$23.5
Fair Value
60.0% undervalued intrinsic discount
6
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/10/30 12:10
End of Day Share Price 2025/10/30 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Delcath Systems, Inc. is covered by 12 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Michael GormanBTIG
Marie ThibaultBTIG
John NewmanCanaccord Genuity